Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Primary borderline retroperitoneal mucinous cystic neoplasm and situs inversus totalis: a case report.

Created on 16 Oct 2026

Authors

Jeude M S Bravo, Igor V Cangussu, Priscila T Tanuri, Giovanna A Rosa, Vaine G S Ribeiro, João Lucas G Correa, Lúcio Fernando D Cachaca, Frederico Augustus M Resende, Eliel O De Araújo

Published in

Journal of surgical case reports. Volume 2026. Issue 10. Pages rjag918. Epub Oct 14, 2026.

Abstract

Primary retroperitoneal mucinous cystic neoplasms (PRMCNs) are rare tumors classified into cystadenoma, PRMCN with borderline malignancy (PRMCN-BM), and cystadenocarcinoma. We report a 60-year-old woman with left flank abdominal pain whose MRI revealed situs inversus totalis alongside a complex cystic lesion in the left retroperitoneum measuring 4.8 × 5.2 × 4.5 cm. She underwent laparotomy with complete resection of the lesion, and histopathology confirmed a primary retroperitoneal neoplasm with borderline malignancy, with an uneventful postoperative course and no recurrence after 8 months. To date, only 35 cases of mucinous cystadenomas with borderline malignancy have been documented in the literature. Clinical presentation is variable, imaging lacks specific diagnostic criteria, and serum tumor markers have no diagnostic value. Surgical resection remains the curative therapeutic approach, and histopathology is essential for the definitive diagnosis, which continues to pose a preoperative challenge.

PMID:
42877923
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement